Skip to main content
GoodMoatv1.3
Sign in
RGNX logo

RGNX

CompareEarnings: Aug 31, 2026

Regenxbio Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne ; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku ; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis ' ZOLGENSMA ®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people.

Current Price

$5.72

-8.41%

GoodMoat Value

$8.23

43.9% undervalued
Profile
Valuation (TTM)
Market Cap$295.23M
P/E-1.02
EV—
P/B2.87
Shares Out51.61M
P/Sales3.36
Revenue$87.82M
EV/EBITDA—

Regenxbio Inc (RGNX) Company Profile

RGNX Company Information

REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy.

REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne ; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku ; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie.

Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis ' ZOLGENSMA ®.

REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people.

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

Maryland, USA

RGNX Key Officers

Key officers data coming soon

RGNX Company Profile

Regenxbio Inc (RGNX) is a Healthcare company in the Biotechnology industry. It trades on NASDAQ. The company is based in Maryland, USA.

REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne ; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku ; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis ' ZOLGENSMA ®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people.

Market cap is $295.23M. There are 51.6M shares outstanding.

See the full Regenxbio Inc profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if RGNX is a good investment.